A case of androgenetic alopecia treated with valproic acid

Choi, Sun Young; Kim, Ha Dong; Kim, Beom Joon; Kim, Myeung Nam; Han, Doug Hyun

doi:10.1111/j.1365-4632.2012.05832.x

Cited by 7 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed that topical SV could effectively increase the total hair count. Choi et al [ 12 ] explored that VA has a potential effect on the hair cycle and could be used to treat AGA. Lee et al [ 10 ] reported that the topical application of VA stimulated hair regrowth in mice and activated alkaline phosphatase activity in human dermal papilla cells by activating the Wnt/β-catenin pathway.…”

Section: Introductionmentioning

confidence: 99%

Formulation of Sodium Valproate Nanospanlastics as a Promising Approach for Drug Repurposing in the Treatment of Androgenic Alopecia

et al. 2020

View full text Add to dashboard Cite

Sodium valproate (SV) is an antiepileptic drug that is widely used in the treatment of ‎different seizure disorders. The topical SV has a hair regenerative potential through activating the Wnt/β-catenin pathway and anagen phase induction‎. The aim of the current investigation was to fabricate nanospanlastics of SV for improving its dermal delivery by providing ‎prolonged drug effect and increasing its permeability ‎for treatment of androgenic alopecia (AGA). SV-loaded nanospanlastics were formulated according to 23 factorial design by ethanol injection method using a non-ionic surfactant (Span 60) and edge activators (EAs), such as Tween 80 and Cremophor RH 40, to explore the influence of different independent variables on entrapment efficiency (EE%) and percentage drug released after 12 h (Q12h) in order to choose the optimized formula using Design-Expert software. The optimized formula (F8) appeared as spherical deformable vesicles with EE% of 90.32 ± 2.18% and Q12h of 90.27 ± 1.98%. F8 exhibited significant improvement of ex vivo permeation than free SV. The clinical study exhibited no comparable difference between F8 and marketed minoxidil lotion. However, F8 demonstrates less adverse effects than minoxidil lotion. Nanospanlastics could be a safe and effective method for improving the topical delivery of SV in the management of AGA.

show abstract

Section: Introductionmentioning

confidence: 99%

Formulation of Sodium Valproate Nanospanlastics as a Promising Approach for Drug Repurposing in the Treatment of Androgenic Alopecia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The interesting biological and structural properties of valeric acid [3][4][5][6][7][8][9][10][11][12] and valproic acid [13][14][15][16][17][18][19][20][21][22][23][24] have prompted the thorough investigation of their conformational profiles for the purpose of comparison. In an earlier study a portable Raman instrument was used to detect the solid form of valeric acid (1800-200 cm À1 ) as part of a study of a series of fundamental organic acids [4].…”

Section: Resultsmentioning

confidence: 99%

A study of the experimental and theoretical infrared, Raman, 1H and 13C NMR spectra of the biochemicals valeric and valproic acids

Badawi

Förner

Ali

2014

Journal of Molecular Structure

View full text Add to dashboard Cite

“…the VPA group's mean change in total hair count increased significantly. To treat AGA, Choi et al (18) looked into the possibility that VA could have an impact on the hair cycle. The unknown mechanism is behind VPA's effects on the hair.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Topical Sodium Valproate-Loaded Nano Spanlastics Formulation versus Minoxidil® 5% in The Treatment of Female Pattern Hair Loss Using Transdermal Delivery: A Comparative Study

Abdel-Moiti¹,

Badria²,

Aly³

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Valproic acid (VPA), is often used as an anticonvulsant drug that activates the Wnt/βcatenin signaling pathway and blocks GSK3b, a glycogen synthase kinase, and though connected with increasing hair growth and induction of anagen. Currently, only FDA-approved two percent topical minoxidil is available therapy to treat female pattern baldness. Objective: This randomized controlled clinical trial study aimed to evaluate the effectiveness of topical VPA and 5% topical minoxidil for treating Female pattern hair loss (FPHL). Patients and methods: This study included 81 patients with FPHL who were allocated into three groups randomly (27 treated with topical sodium valproate-loaded nano spanlastics formulation, 27 treated with minoxidil® 5% lotion, and 27 treated with saline bottled containers using transdermal delivery using a derma roller for 6 months. The included patients were chosen randomly from the Outpatient Clinic of Dermatology, Andrology & STDs Department, Mansoura University Hospitals. All patients were subjected to history taking, and general dermatological and scalp examination. Results:In comparison to the control group, the mean change in the total number of hairs was substantially larger in the VPA and minoxidil groups (P = 0.047). Although the majority of adverse events in both groups were moderate and self-limiting, the variations in prevalence rates across the groups were comparable (P = 0.72). Conclusion: Topical VPA and 5% minoxidil increased the total hair count of our patients ; therefore, topical VPA is a potential therapy option for FPHL.

show abstract

A case of androgenetic alopecia treated with valproic acid

Cited by 7 publications

References 5 publications

Formulation of Sodium Valproate Nanospanlastics as a Promising Approach for Drug Repurposing in the Treatment of Androgenic Alopecia

Formulation of Sodium Valproate Nanospanlastics as a Promising Approach for Drug Repurposing in the Treatment of Androgenic Alopecia

A study of the experimental and theoretical infrared, Raman, 1H and 13C NMR spectra of the biochemicals valeric and valproic acids

Evaluation of Topical Sodium Valproate-Loaded Nano Spanlastics Formulation versus Minoxidil® 5% in The Treatment of Female Pattern Hair Loss Using Transdermal Delivery: A Comparative Study

Contact Info

Product

Resources

About